Home・Elenco Azioni・CRISPR Therapeutics AG

CRISPR Therapeutics AG

Aperta

SettoreSettore sanitario

52.85 7.09

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

48.94

Massimo

52.47

Metriche Chiave
By Trading Economics
Entrata	7.7M -123M
Vendite	594K 1.5M
EPS	-1.28
Margine di Profitto	-8,431.481
Dipendenti	393
EBITDA	31M -118M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+50.21% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-315M 4.6B
Apertura precedente	45.76
Chiusura precedente	52.85

Notizie sul Sentiment di mercato

By Acuity

24%

76%

67 / 340 Classifica in Healthcare

CRISPR Therapeutics AG Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 ago 2026, 23:02 UTC

Social Media

News

CRISPR Therapeutics reported second-quarter revenue of $10.18 million, exceeding expectations. Shares are trading higher in after-market hours following the earnings report.

31 lug 2026, 23:06 UTC

Shares of CRISPR Therapeutics AG are trading higher in after-market hours. The stock remains near the lower end of its one-month trading range.

30 lug 2026, 23:02 UTC

News

CRISPR Therapeutics shares are lower in after-market hours amid broader market weakness, despite analysts projecting revenue growth and a price target of $83.53.

29 lug 2026, 22:01 UTC

CRISPR Therapeutics AG shares are lower in after-market trading amid broader market declines driven by geopolitical tensions and caution ahead of the Fed's interest rate decision.

28 lug 2026, 23:01 UTC

Correlated Moves

CRISPR Therapeutics AG shares are lower in after-market trading, reflecting broader market trends and a decline in the Russell 2000 Index.

27 lug 2026, 19:07 UTC

CRISPR Therapeutics AG shares are higher today, gaining since Friday's close. The stock peaked earlier in the session before pulling back.

23 lug 2026, 10:36 UTC

CRISPR Therapeutics AG shares are roughly flat in pre-market hours, with no specific company news identified. The stock remains near the lower end of its trading range.

22 lug 2026, 23:06 UTC

CRISPR Therapeutics AG shares are trading higher in after-market hours, though they remain below their 20-day moving average and near the lower end of their one-month range.

21 lug 2026, 19:26 UTC

News

Correlated Moves

CRISPR Therapeutics AG shares are higher today, buoyed by a strong gene-editing pipeline and positive analyst sentiment regarding its lead asset, CASGEVY.

20 lug 2026, 23:22 UTC

CRISPR Therapeutics AG is trading higher in after-market hours, despite broader market declines linked to rising treasury yields. No specific news was identified.

Confronto tra pari

Modifica del prezzo

CRISPR Therapeutics AG Previsione

Obiettivo di Prezzo

By TipRanks

50.21% in crescita

Previsioni per 12 mesi

Media 74.46 USD 50.21%

Alto 110 USD

Basso 45 USD

Basato su 14 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per CRISPR Therapeutics AG - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

14 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 14 che hanno fornito valutazioni azionarie a CRISPR Therapeutics AG - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

67 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.